Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02613598
Title Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

non-Hodgkin lymphoma

Hodgkin's lymphoma

Therapies

Bortezomib + Ruxolitinib

Age Groups: adult
Covered Countries USA


No variant requirements are available.